Drug Targeting Organ-Specific Strategies

More documents

Recommendations

Info

330 12 Use of Human Tissue Slices in Drug Targeting Research [72] Leeman WR, van de Gevel IA, Rutten AAJJL, Toxicol. In Vitro 1995, 9, 291–298. [73] de Kanter R, Olinga P, de Jager MH, Merema MT, Meijer DKF, Groothuis GMM, Toxicol. In Vitro 1999, 13, 737–744. [74] de Kanter R, Olinga P, Hof I, de Jager M, Verwillegen WA, Slooff MJ, Koster HJ, Meijer DK, Groothuis GM, Xenobiotica 1998, 28, 225–234. [75] Olinga P, Merema M, Hof IH, de Jong KP, Slooff MJH, Meijer DKF, Groothuis GMM, Drug Metab. Dispos. 1998, 26, 5–11. [76] Valentovic MA, Ball JG, Anestis DK, Rankin GO, Toxicol. In Vitro 1995, 9, 75–81. [77] Miller MG, Beyer J, Hall GL, Degraffenried LA, Adams PE, Toxicol. Appl. Pharmacol. 1993, 122, 108–116. [78] Olinga P, Merema MT, Hof IH, De Jager MH, De Jong KP, Slooff MJH, Meijer DKF, Groothuis GMM, Xenobiotica 1998, 28, 349–360. [79] Jansen RW, Olinga P, Harms G, Meijer DKF, Pharm. Res. 1993, 10, 1611–1614. [80] Sutto F, Brault A, Lepage R, Huet P-M, J. Hepatol. 1994, 20, 611–616. [81] Olinga P, Hof IH, Smit M, de Jager MH, Nijenhuis E, Slooff MJH, Meijer DKF, Groothuis GMM, J. Pharm. Toxicol. Methods, 2001 (in press). [82] Oude Elferink RPJ, Meijer DKF, Kuipers F, Jansen PLM, Groen AK, Groothuis GMM, Biochim. Biophys. Acta 1995, 1241, 215–268. [83] Tiribelli C, Reichen J, Meijer DKF, J. Hepatol. 1996, 24, 11–34. [84] Meijer DKF, In: Handbook of Physiology. The Gastrointestinal System, Vol. III (Eds Schulz J, Forte G, Rauner BB), pp. 717–758. Oxford University Press, New York, 1989. [85] Meijer DKF, Ziegler K, In: Biological Barriers to Protein Delivery (Eds Audus KL, Raub TJ), pp. 339–407. Plenum Press, New York and London, 1993. [86] Jansen RW, Kruijt JK, van Berkel TJ, Meijer DK, Hepatology 1993, 18, 146–152. [87] Olinga P, Merema MT, Hof IH, Slooff MJH, Proost JH, Meijer DKF, Groothuis GMM, J. Pharmacol. Exp. Ther. 1998, 285, 506–510. [88] Sandker GW, Weert B, Olinga P, Wolters H, Slooff MJH, Meijer DKF, Groothuis GMM, Biochem. Pharmacol. 1994, 47, 2193–2200. [89] Schanker LS, Solomon HM, Am. J. Physiol. 1963, 204, 829–832. [90] Hedman A, Meijer DKF, J. Pharm. Sci. 1998, 87, 457–461. [91] Hedman A, Meijer DK, J. Hepatol. 1998, 28, 240–249. [92] Olinga P, de Kanter R, Hof IH, de Jager MH, Slooff MJH, Koster HJ, Meijer DKF, Groothuis GMM, Hepatology 1996, 24, 468A. [93] Thompson MB, Davis DG, Morris RW, J. Lipid Res. 1993, 34, 553–561. [94] Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GMM, Meijer DKF, Poelstra K, Hepatology 1999, 29, 1486–1493. [95] Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, Meijer DKF, Poelstra K, J. Biol. Chem. 2000, 275, 12743–12751. [96] Aono K, Isobe K, Kiuchi K, Fan ZH, Ito M, Takeuchi A, Miyachi M, Nakashima I, Nimura Y, J. Cell Biochem. 1997, 65, 349–358. [97] Van Bossuyt H, De Zanger RB, Wisse E, J. Hepatol. 1988, 7, 325–337. [98] Billiar TR, Curran RD, Ferrari FK, Williams DL, Simmons RL, J. Surg. Res. 1990, 48, 349–353. [99] Vos TA, Gouw AS, Klok PA, Havinga R, van Goor H, Huitema S, Roelofsen H, Kuipers F, Jansen PL, Moshage H, Gastroenterology 1997, 113, 1323–1333. [100] Nussler AK, Di Silvio M, Liu ZZ, Geller DA, Freeswick P, Dorko K, Bartoli F, Billiar TR, Hepatology 1995, 21, 1552–1560. [101] Luster MI, Germolec DR, Yoshida T, Kayama F, Thompson M, Hepatology 1994, 19, 480–488. [102] Sultan K, Hartung J, Bade EG, FEBS Lett. 1996, 394, 51–54. [103] Melgert BN, Olinga P, Jack VK, Molema G, Meijer DKF, Poelstra K, J. Hepatol. 2000, 32, 603–611. [104] Olinga P, Merema MT, de Jager MH, Slooff MJH, Limburg PC, Bijzet J, Poelstra K, Meijer DKF, Groothuis GMM, Hepatology 1998, 28, 184A. [105] Stijntjes GJ, Commandeur JN, te Koppele JM, McGuinness S, Gandolfi AJ, Vermeulen NP, Toxicology 1993, 79, 67–79. [106] Vickers AEM, Fisher RL, Brendel K, Guertler J, Dannecker R, Keller B, Fischer V, Drug Metab. Dispos. 1995, 23, 327–333. [107] Foulkes EC, Proc. Soc. Exp. Biol. Med. 1996, 211, 155–162. [108] Ruegg CE, Gandolfi AJ, Nagle RB, Krumdieck CL, Brendel K, J. Pharmacol. Methods 1987, 17, 111–123.
References 331 [109] Dutt A, Priebe TS, Teeter LD, Kuo MT, Nelson JA, J. Pharmacol. Exp. Ther. 1992, 261, 1222–1230. [110] Drieman JC, Thijssen HH, Struyker-Boudier HA, Br. J. Pharmacol. 1993, 108, 204-208. [111] Rump LC, Schwertfeger E, Schaible U, Schuster MJ, Frankenschmidt A, Schollmeyer P, Eur. J. Clin. Pharmacol. 1993, 44 (Suppl. 1), S47–S49. [112] Stubenitsky BM, Ametani M, Danielewicz R, Southard JH, Belzer FO, Transplant. Int. 1995, 8, 293–297. [113] Gonzalez-Flecha B, Evelson P, Sterin-Speziale N, Boveris A, Biochim. Biophys. Acta 1993, 1157, 155–161. [114] Hoet PH, Lewis CP, Demedts M, Nemery B, Biochem. Pharmacol. 1994, 48, 517–524. [115] Placke ME, Fisher GL, Toxicol. Appl. Pharmacol. 1987, 90, 284–298. [116] Price RJ, Renwick AB, Wield PT, Beamand JA, Lake BG, Arch. Toxicol. 1995, 69, 405–409. [117] Price RJ, Renwick AB, Beamand JA, Esclangon F, Wield PT, Walters DG , Lake BG, Food Chem. Toxicol. 1995, 33, 233–237. [118] Fisher RL, Smith MS, Hasal SJ, Hasal KS, Gandolfi AJ, Brendel K, Hum. Exp. Toxicol. 1994, 13, 466–471.
Page 1 and 2:
Drug Targeting Organ-Specific Strat
Page 3 and 4:
Page 5 and 6:
Preface Drug Targeting Organ-Specif
Page 7 and 8:
Foreword Drug Targeting Organ-Speci
Page 9 and 10:
X List of Contributors Henderik W.
Page 11 and 12:
XII List of Contributors Grietje Mo
Page 13 and 14:
Contents Drug Targeting Organ-Speci
Page 15 and 16:
Contents XVII 3 Pulmonary Drug Deli
Page 17 and 18:
Contents XIX 5.2.1.6 Identification
Page 19 and 20:
Contents XXI 7.5 In Vitro Technique
Page 21 and 22:
Contents XXIII 9.4 Tumour Vasculatu
Page 23 and 24:
Contents XXV 12.8. Tissue Slices fr
Page 25 and 26:
Page 27 and 28:
Dexa dexamethasone DIVEMA divinyl e
Page 29 and 30:
LRP lung resistance related protein
Page 31 and 32:
ROS reactive oxygen species RSV res
Page 33 and 34:
Index a ADEPT 217, 224, 268, 291 ad
Page 35 and 36:
e E. coli expression system 292 eff
Page 37 and 38:
polymers, soluble 4, 218 - dendrime
Page 39 and 40:
2 1 Drug Targeting: Basic Concepts
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
24 2 Brain-Specific Drug Targeting
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
54 3 Pulmonary Drug Delivery: Deliv
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
4 Cell Specific Delivery of Anti-In
Page 127 and 128:
The sinusoids are lined by the disc
Page 129 and 130:
4.2.2.2 Phagocytosis and Transcytos
Page 131 and 132:
ther inflammatory cells or accessor
Page 133 and 134:
4.3 Hepatic Inflammation and Fibros
Page 135 and 136:
process is not yet available. Sever
Page 137 and 138:
this carrier to the KCs.When the ma
Page 139 and 140:
e taken up rapidly by mannose recep
Page 141 and 142:
y the transcriptional regulatory pr
Page 143 and 144:
4.8 Testing Liver Targeting Prepara
Page 145 and 146:
4.8 Testing Liver Targeting Prepara
Page 147 and 148:
4.9 Targeting of Anti-inflammatory
Page 149 and 150:
4.9 Targeting of Anti-inflammatory
Page 151 and 152:
with monoclonal and bispecific anti
Page 153 and 154:
References 117 [50] Coleman DL, Eur
Page 155 and 156:
References 119 [133] Cronstein BN,
Page 157 and 158:
5 Delivery of Drugs and Antisense O
Page 159 and 160:
5.1 Introduction 123 convoluted tub
Page 161 and 162:
treatment of the targeted cell and
Page 163 and 164:
CL uptake (ml/min/g) centration pro
Page 165 and 166:
5.2.1.4 Specific Binding of Alkylgl
Page 167 and 168:
5.2 Renal Delivery Using Pro-Drugs
Page 169 and 170:
5.2 Renal Delivery Using Pro-Drugs
Page 171 and 172:
5.3 Renal Delivery Using Macromolec
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
5.4 Renal Delivary of Antisense Oli
Page 183 and 184:
5.4 Renal Delivery of Antisense Oli
Page 185 and 186:
5.4.8 Benefits and Limitations of A
Page 187 and 188:
via reabsorption from the luminal s
Page 189 and 190:
References 153 [66] Franssen EJF, M
Page 191 and 192:
References 155 [145] Van Zwieten PA
Page 193 and 194:
158 6 A Practical Approach in the D
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
172 7 Vascular Endothelium in Infla
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
8 Strategies for Specific Drug Targ
Page 235 and 236:
8.2.2 Histogenesis The traditional
Page 237 and 238:
may become obstructed and compresse
Page 239 and 240:
8.5 Strategies to Deliver Drugs to
Page 241 and 242:
8.5 Strategies to Deliver Drugs to
Page 243 and 244:
larly cytotoxic immune effector cel
Page 245 and 246:
contributes to limited tumour penet
Page 247 and 248:
ples onto anti-EGP-2 scFv. Biologic
Page 249 and 250:
In the case of drug-monoclonal anti
Page 251 and 252:
cells, the presence of co-stimulato
Page 253 and 254:
Monomethoxy-polyethylene glycol CH
Page 255 and 256:
e efficiently loaded into the lipos
Page 257 and 258:
8.6 Clinical Studies 223 Table 8.5.
Page 259 and 260:
8.6.3 (Synthetic) (co)Polymers Solu
Page 261 and 262:
8.8 Conclusions and Future Perspect
Page 263 and 264:
References 229 [43] Chaouchi NA, Va
Page 265 and 266:
References 231 [126] Czuczman MS, G
Page 267 and 268:
234 9 Tumour Vasculature Targeting
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
256 10 Phage Display Technology for
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
11 Development of Proteinaceous Dru
Page 309 and 310:
carrier is an homogenous product. I
Page 311 and 312: 11.3 The Homing Device 11.3 The Hom
Page 313 and 314: malian cell lines that have acquire
Page 315 and 316: jugates for the delivery of other a
Page 317 and 318: 11.5 The Linkage Between Drug and C
Page 319 and 320: actions are directed towards these
Page 321 and 322: 11.5 The Linkage Between Drug and C
Page 323 and 324: homing potential if the antigen rec
Page 325 and 326: ly used promoters include T7 RNA po
Page 327 and 328: the baculovirus expression vector,
Page 329 and 330: 11.8 Recombinant DNA Constructs 297
Page 331 and 332: 11.8 Recombinant DNA Constructs 299
Page 333 and 334: toxic activity. Anthrax and tetanus
Page 335 and 336: 11.9 Recombinant Domains as Buildin
Page 337 and 338: References 305 [16] Milstein C, Wal
Page 339 and 340: References 307 [99] Verma R, Boleti
Page 341 and 342: 12 Use of Human Tissue Slices in Dr
Page 343 and 344: are also extensively used in a vari
Page 345 and 346: Meanwhile many incubation systems h
Page 347 and 348: 12.3 Incubation and Culture of Live
Page 349 and 350: to investigate the effect of differ
Page 351 and 352: The mechanisms of uptake and excret
Page 353 and 354: 12.6 The Use of Liver Slices in Dru
Page 355 and 356: 12.7 Efficacy Testing of the Drug T
Page 357 and 358: NO x µM 80 60 40 20 * * 12.7 Effic
Page 359 and 360: TNFα ng/ml 1.5 1 0.5 0 * Human (n=
Page 361: References 329 [33] Ikejima K, Enom
Page 365 and 366: 334 13 Pharmacokinetic/Pharmacodyna
Page 403 and 404: 372 14 Drug Targeting Strategy: Scr
Page 405 and 406: 374 14 Drug Targeting Strategy: Scr
show all

Drug Targeting Organ-Specific Strategies

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?